Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 315
- Registration Number
- NCT01302392
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Non-Secretory Plasma Cell MyelomaPlasmacytosisRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT01301807
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
- Conditions
- Myeloma
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT01279694
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT01246063
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
- Conditions
- Recurrent Small Lymphocytic LymphomaB-cell Chronic Lymphocytic LeukemiaHematopoietic/Lymphoid CancerProlymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia
- Interventions
- Other: Cytokine AssessmentOther: Pharmacodynamic StudiesOther: Proteosome Inhibition AssessmentOther: Pharmacogenomic Studies
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2016-05-09
- Target Recruit Count
- 21
- Registration Number
- NCT01212380
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
- Conditions
- Blast CrisisAMLMultiple MyelomaALLMDS
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01204164
- Locations
- 🇺🇸
MDACC, Houston, Texas, United States
🇺🇸RMCC, Denver, Colorado, United States
🇺🇸Cornell, New York City, New York, United States
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT01137747
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
- Conditions
- Relapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 792
- Registration Number
- NCT01080391
- Locations
- 🇺🇸
Providence St. Joseph Medical Center, Burbank, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
- Conditions
- Multiple MyelomaStage III Multiple MyelomaStage II Multiple MyelomaStage I Multiple Myeloma
- Interventions
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 64
- Registration Number
- NCT01057225
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
UARK 2009-32 Compassionate Use Study of Carfilzomib
- Conditions
- Multiple Myeloma
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT00999414
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.